Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06135584
NA

Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies

Sponsor: The Affiliated Hospital of Hangzhou Normal University

View on ClinicalTrials.gov

Summary

To establish a prospective, multicenter, biopsie-confirmed clinical cohort of MAFLD-related cirrhosis (F3-F4) in China, and analyze the clinical, histopathological features and natural outcomes of MAFLD-associated liver fibrosis/cirrhosis in China. And than to conducted a real-world study of different strategies of Chinese characteristics for the prevention and treatment of MAFLD-related cirrhosis to evaluate the efficacy and safety of the strategies.

Official title: Prospective Cohort Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

1000

Start Date

2023-11-18

Completion Date

2026-12-31

Last Updated

2023-11-18

Healthy Volunteers

No

Interventions

DRUG

Pioglitazone metformin tablets

Drug intervention for 24 weeks and follow-up for another 72 weeks (fasting blood glucose was controlled below 7.0mmol/l throughout the study)

DRUG

Other drugs

Chinese patent medicine or hypoglycemic drugs other than pioglitazone metformin tablets, pioglitazone, metformin, GLP1

OTHER

Drug-free

Drug-free